Regulatory activity of azabisphosphonate-capped dendrimers on human CD4 + T cell proliferation enhances ex-vivo expansion of NK cells from PBMCs for immunotherapy

Journal of Translational Medicine

Volumn 7, Issue , 2009, Pages 82-

  Portevin, Damien ^a,b   Poupot, Mary ^a,b   Rolland, Olivier ^b   Turrin, Cédric Olivier ^b   Fournié, Jean Jacques ^a,b   Majoral, Jean Pierre ^b   Caminade, Anne Marie ^b   Poupot, Remy ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

Cancer; CD4; Cell expansion; Dendrimer; Immunotherapy; NK

Indexed keywords

AZABISPHOSPHONATE; BISPHOSPHONIC ACID DERIVATIVE; DENDRIMER; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CELL EXPANSION; CELL SELECTION; CELL VIABILITY; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ANIMAL; CELL CULTURE; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; CYTOLOGY; DRUG EFFECT; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METHODOLOGY; MONONUCLEAR CELL; PHYSIOLOGY;

ADULT; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; DENDRIMERS; DIPHOSPHONATES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MOLECULAR STRUCTURE;

EID: 70350106736     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-7-82     Document Type: Article

References (34)

1. Anfossi N, Andre P, Guia S, Falk CS, Roetynck S, Stewart CA, Breso V, Frassati C, Reviron D, Middleton D, et al: Human NK cell education by inhibitory receptors for MHC class I. Immunity 2006, 25:331-342.
2. Cooper MA, Fehniger TA, Caligiuri MA: The biology of uman natural killercell subsets. Trends Immunol 2001, 2:633-640.
3. Poli A, Michel T, Theresine M, Andres E, Hentges F, Zimmer J: CD56bright natural killer (NK) cells: an important NK cell subset. Immunology 2009, 126:458-465.
4. Kiessling R, Klein E, Wigzell H: "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol 1975, 5:112-117.
5. Karre K: NK cells, MHC class I molecules and the missing self. Scand J Immunol 2002, 55:221-228.
6. Karre K: Natural killer cell recognition of missing self. Nat Immunol 2008, 9:477-480.
7. Lanier LL: NK cell recognition. Annu Rev Immunol 2005, 23:225-274.
8. Uhrberg M: Shaping the human NK cell repertoire: an epigenetic glance at KIR gene regulation. Mol Immunol 2005, 42:471-475.
9. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, et al: Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
10. Ruggeri L, Mancusi A, Capanni M, Urbani E, Carotti A, Aloisi T, Stern M, Pende D, Perruccio K, Burchielli E, et al: Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007, 110:433-440.
11. Lundqvist A, McCoy JP, Samsel L, Childs R: Reduction of GVHD and enhanced antitumor effects after adoptive infusion of alloreactive Ly49-mismatched NK cells from MHC-matched donors. Blood 2007, 109:3603-3606.
12. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, Le C, Defor TE, Burns LJ, et al: Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005, 105:3051-3057.
13. Malmberg KJ, Bryceson YT, Carlsten M, Andersson S, Bjorklund A, Bjorkstrom NK, Baumann BC, Fauriat C, Alici E, Dilber MS, Ljunggren HG: NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy. Cancer Immunol Immunother 2008, 57:1541-1552.
14. Ruggeri L, Mancusi A, Perruccio K, Burchielli E, Martelli MF, Velardi A: Natural killer cell alloreactivity for leukemia therapy. J Immunother 2005, 28:175-182.
15. Alici E, Sutlu T, Bjorkstrand B, Gilljam M, Stellan B, Nahi H, Quezada HC, Gahrton G, Ljunggren HG, Dilber MS: Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. Blood 2008, 111:3155-3162.
16. Medina SH, El-Sayed ME: Dendrimers as Carriers for Delivery of Chemotherapeutic Agents. Chem Rev 2009, 109:3141-3157.
17. Vannucci L, Fiserova A, Sadalapure K, Lindhorst TK, Kuldova M, Rossmann P, Horvath O, Kren V, Krist P, Bezouska K, et al: Effects of N-acetyl-glucosamine-coated glycodendrimers as biological modulators in the B16F10 melanoma model in vivo. Int J Oncol 2003, 23:285-296.
18. Sheng KC, Kalkanidis M, Pouniotis DS, Esparon S, Tang CK, Apostolopoulos V, Pietersz GA: Delivery of antigen using a novel mannosylated dendrimer potentiates immunogenicity in vitro and in vivo. Eur J Immunol 2008, 38:424-436.
19. Poupot M, Griffe L, Marchand P, Maraval A, Rolland O, Martinet L, L'Faqihi-Olive FE, Turrin CO, Caminade AM, Fournie JJ, et al: Design of phosphorylated dendritic architectures to promote human monocyte activation. Faseb J 2006, 20:2339-2351.
20. Rolland O, Griffe L, Poupot M, Maraval A, Ouali A, Coppel Y, Fournie JJ, Bacquet G, Turrin CO, Caminade AM, et al: Tailored control and optimisation of the number of phosphonic acid termini on phosphorus-containing dendrimers for the ex-vivo activation of human monocytes. Chemistry 2008, 14:4836-4850.
21. Fruchon S, Poupot M, Martinet L, Turrin CO, Majoral JP, Fournie JJ, Caminade AM, Poupot R: Anti-inflammatory and immunosuppressive activation of human monocytes by a bioactive dendrimer. J Leukoc Biol 2009, 85:553-562.
22. Griffe L, Poupot M, Marchand P, Maraval A, Turrin CO, Rolland O, Metivier P, Bacquet G, Fournie JJ, Caminade AM, et al: Multiplication of human natural killer cells by nanosized phosphonate-capped dendrimers. Angew Chem Int Ed Engl 2007, 46:2523-2526.
23. Ghiringhelli F, Menard C, Terme M, Flament C, Taieb J, Chaput N, Puig PE, Novault S, Escudier B, Vivier E, et al: CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med 2005, 202:1075-1085.
24. Ralainirina N, Poli A, Michel T, Poos L, Andres E, Hentges F, Zimmer J: Control of NK cell functions by CD4+CD25+ regulatory T cells. J Leukoc Biol 2007, 81:144-153.
25. Thornton AM, Donovan EE, Piccirillo CA, Shevach EM: Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function. J Immunol 2004, 172:6519-6523.
26. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, Fazekas de St Groth B, et al: CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006, 203:1701-1711.
27. Carlens S, Gilljam M, Chambers BJ, Aschan J, Guven H, Ljunggren HG, Christensson B, Dilber MS: A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells. Hum Immunol 2001, 62:1092-1098.
28. Jin Y, Knudsen E, Wang L, Bryceson Y, Damaj B, Gessani S, Maghazachi AA: Sphingosine 1-phosphate is a novel inhibitor of T-cell proliferation. Blood 2003, 101:4909-4915.
29. Miller JS, Oelkers S, Verfaillie C, McGlave P: Role of monocytes in the expansion of human activated natural killer cells. Blood 1992, 80:2221-2229.
30. Dunne J, Lynch S, O'Farrelly C, Todryk S, Hegarty JE, Feighery C, Doherty DG: Selective expansion and partial activation of human NK cells and NK receptor-positive T cells by IL-2 and IL-15. J Immunol 2001, 167:3129-3138.
31. Walker MR, Kasprowicz DJ, Gersuk VH, Benard A, Van Landeghen M, Buckner JH, Ziegler SF: Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. J Clin Invest 2003, 112:1437-1443.
32. Klenerman P, Cerundolo V, Dunbar PR: Tracking T cells with tetramers: new tales from new tools. Nat Rev Immunol 2002, 2:263-272.
33. Poupot M, Fournie JJ: Non-peptide antigens activating human Vgamma9/Vdelta2 T lymphocytes. Immunol Lett 2004, 95:129-138.
34. Mestel DS, Assaf C, Steinhoff M, Beyer M, Moebs M, Sterry W: Emerging drugs in cutaneous T cell lymphoma. Expert Opin Emerg Drugs 2008, 13:345-361.